HAE Price Prediction Next Week
Haemonetics (HAE) Stock Price Prediction and Recommendation
News Analysis:
- Price Target Adjustment: JMP Securities lowered HAE's price target from $125 to $100, citing weaker-than-expected Plasma and Hospital revenues and disappointing performance from new technologies Opsens and Attune. Despite challenges, JMP believes HAE's new products hold significant potential in the plasma collection industry.
- Stock Downgrade: Bank of America downgraded HAE to Underperform, concerned about lower FY25 outlook and revenue miss in Q3, particularly in plasma and Vascade segments. They also highlighted negative impacts from proposed tariffs on Canada and Mexico.
- USMCA Exemption: A one-month exemption for USMCA-compliant goods is seen as beneficial for HAE due to its exposure to Mexico.
Technical Analysis:
- Current Price: $64.45 as of 2025-03-24.
- RSI: 40.20, indicating oversold conditions, suggesting potential for a bounce.
- MACD: Negative, indicating downward momentum.
- Fibonacci Levels: Resistance at $67.98 and support at $63.62.
Price Prediction:
Based on the analysis, HAE is expected to trade between $63.62 and $67.98 next week, with a slight bearish bias due to downgrades and revenue concerns.
Recommendation:
Sell HAE at resistance near $67.98, as the stock faces headwinds from downgrades and revenue issues. Consider buying on dips near the support level of $63.62 if market conditions improve.
HAE Similar Chart Price Prediction
The price of HAE is predicted to go up 30.5%, based on the high correlation periods with SCS. The similarity of these two price pattern on the periods is 96.8%.
HAE
SCS
Up: 30.5%Similarity: 96.8%
HAE Revenue Forecast
HAE EPS Forecast
HAE FAQs
What is HAE revenue forecast for next quarter？
What is HAE eps forecast for next quarter？
HAE Analyst's Forecast
Mike Matson
Needham
Strong Buy
2025-03-18
Price Target
$108 → $104
Upside
+60.79%
Needham analyst Mike Matson lowered the firm's price target on Haemonetics to $104 from $108 and keeps a Buy rating on the shares. The firm is adjusting its model after the company completed the sale of its whole blood assets to GVS, S.p.A, the analyst tells investors in a research note. Needham is also cutting its FY26 EPS view by 22c to $4.99, though the firm expects Haemonetics to sustain mid- to high-single digit growth, driven by high-single digit or better non-CSL Plasma growth and mid-teens or better Hospital growth.
Rohin Patel
JP Morgan
Buy
2024-12-06
Price Target
$116
Upside
+42.87%
Andrew Cooper
Raymond James
Buy → Strong Buy
2024-11-08
Price Target
$120
Upside
+37.27%
